Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
1.20
Oct 22 • 3:57 PM ET Dollar change-0.07 Percentage change(-5.51%)
Aftermarket Close
1.20
Aftermarket • 5:20 PM ET Dollar change0.00 Percentage change(0.00%)
Today, 5:36 PMMindWalk Holdings Corp. announces that Chief Business Officer Thomas Lynch has departed the company, with commercial and business development functions now reporting directly to the CEO.
Index
-
Market Cap
56.53M
Enterprise Value
53.58M
Income
-12.31M
Sales
11.72M
Book/sh
0.10
Cash/sh
0.12
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
77
IPO
Nov 06, 2003
P/E
-
Forward P/E
-
PEG
-
P/S
4.82
P/B
11.45
P/C
10.41
P/FCF
-
EV/EBITDA
-
EV/Sales
4.57
Quick Ratio
1.75
Current Ratio
1.84
Debt/Eq
0.50
LT Debt/Eq
0.43
Option/Short
Yes / Yes
EPS (ttm)
-0.26
EPS next Y
-0.25
EPS next Q
-0.06
EPS this Y
-22.92%
EPS next Y
14.00%
EPS next 5Y
4.19%
EPS past 3/5Y
35.25% 8.52%
Sales past 3/5Y
-10.15% -3.79%
EPS Y/Y TTM
56.50%
Sales Y/Y TTM
-26.89%
EPS Q/Q
-99.36%
Sales Q/Q
19.36%
Insider Own
9.45%
Insider Trans
0.00%
Inst Own
9.27%
Inst Trans
-0.62%
ROA
-58.96%
ROE
-123.73%
ROIC
-174.26%
Gross Margin
60.79%
Oper. Margin
-104.08%
Profit Margin
-105.08%
SMA20
-13.04%
SMA50
-12.03%
SMA200
-16.62%
Trades
Shs Outstand
46.99M
Shs Float
42.66M
52W High
2.99 -59.87%
52W Low
0.99 21.21%
Volatility
7.04% 7.72%
ATR (14)
0.11
RSI (14)
38.95
Beta
0.77
Rel Volume
0.90
Avg Volume
240.51K
Volume
215,660
Perf Week
-14.29%
Perf Month
-13.67%
Perf Quarter
-11.76%
Perf Half Y
0.00%
Perf YTD
-34.07%
Perf Year
-17.24%
Perf 3Y
5.26%
Perf 5Y
-80.61%
Perf 10Y
6053.85%
Prev Close
1.27
Price
1.20
Change %
-5.51%
Date Action Analyst Rating Change Price Target Change
Dec-02-22Initiated H.C. Wainwright Buy $9
Oct-25-21Initiated The Benchmark Company Buy $12
MindWalk Holdings Corp. is an AI-driven biotherapeutic research, technology, and scientifically robust life science company that discovers and develops customized and novel antibodies by generating proprietary and patented processes, procedures, and innovative approaches to antibody discovery, development, and production. It operates through the following geographical segments: United States of America, Europe, Canada, Australia, and Other. The company was founded by Robert Beecroft on November 22, 1983 and is headquartered in Austin, TX.
CEODr. Jennifer Lynne Bath Ph.D.
Chief Financial OfficerMr. Richard Scott Areglado
Chief Business OfficerDr. Thomas Lynch Ph.D.
Vice President of Commercial ServicesMs. Kari Graber
Vice President of Innovative SolutionsDr. Shuji Sato